Clinical Trial Update: Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial is evaluating Trastuzumab deruxtecan (T-DXd) alone or in sequence with THP versus standard ddAC-THP in HER2-positive early breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• Pertuzumab (pertuzumab)
• Trastuzumab (trastuzumab)
• Trastuzumab deruxtecan (trastuzumab deruxtecan)

Snippet

Sponsor: AstraZeneca | Conditions: Breast Neoplasms, Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING